These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 32654064)

  • 41. A long-term follow-up of rituximab treatment in 20 Chinese patients with neuromyelitis optica spectrum disorders.
    Lu Q; Luo J; Hao H; Liu R; Jin H; Jin Y; Gao F
    Mult Scler Relat Disord; 2020 May; 40():101933. PubMed ID: 31955136
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Development of RISS in two patients with NMOSD undergoing rituximab treatment: a case report.
    Ersöz AS; Yaşargün DÖ; Mısırlı CH
    Acta Neurol Belg; 2024 Jun; 124(3):1041-1042. PubMed ID: 37904077
    [No Abstract]   [Full Text] [Related]  

  • 43. Hiccups as Herald: Neuromyelitis Optica Spectrum Disorder.
    Puri A; Chesser M; Chan K; Kharidi V
    Am J Med; 2017 Sep; 130(9):1055-1058. PubMed ID: 28599993
    [No Abstract]   [Full Text] [Related]  

  • 44. Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial.
    Tahara M; Oeda T; Okada K; Kiriyama T; Ochi K; Maruyama H; Fukaura H; Nomura K; Shimizu Y; Mori M; Nakashima I; Misu T; Umemura A; Yamamoto K; Sawada H
    Lancet Neurol; 2020 Apr; 19(4):298-306. PubMed ID: 32199095
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Rituximab in relapsing-remitting multiple sclerosis.
    De Palma R; Sementa A
    N Engl J Med; 2008 Jun; 358(24):2645-6; author reply 2646-7. PubMed ID: 18550883
    [No Abstract]   [Full Text] [Related]  

  • 46. Efficacy and safety of rituximab in relapsing-remitting multiple sclerosis: A systematic review and meta-analysis.
    Tian X; Chen C; Ma L; Wei R; Li M; Wang X; Wu Y; Zhou Y; Cui Y
    J Neuroimmunol; 2020 Oct; 347():577317. PubMed ID: 32731048
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Rituximab in relapsing-remitting multiple sclerosis.
    Schrijver HM
    N Engl J Med; 2008 Jun; 358(24):2645; author reply 2646-7. PubMed ID: 18557177
    [No Abstract]   [Full Text] [Related]  

  • 48. Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study.
    Annovazzi P; Capobianco M; Moiola L; Patti F; Frau J; Uccelli A; Centonze D; Perini P; Tortorella C; Prosperini L; Lus G; Fuiani A; Falcini M; Martinelli V; Comi G; Ghezzi A
    J Neurol; 2016 Sep; 263(9):1727-35. PubMed ID: 27286847
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Rituximab for relapsing-remitting multiple sclerosis.
    He D; Zhou H; Han W; Zhang S
    Cochrane Database Syst Rev; 2011 Dec; (12):CD009130. PubMed ID: 22161445
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Aquaporin-4 serostatus does not predict response to immunotherapy in neuromyelitis optica spectrum disorders.
    Mealy MA; Kim SH; Schmidt F; López R; Jimenez Arango JA; Paul F; Wingerchuk DM; Greenberg BM; Kim HJ; Levy M
    Mult Scler; 2018 Nov; 24(13):1737-1742. PubMed ID: 28857723
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Individualized rituximab treatment for relapsing neuromyelitis optica: a pediatric case report.
    He D; Yu Y; Yan W; Dai Q; Xu Z; Chu L
    Pediatr Neurol; 2014 Aug; 51(2):255-8. PubMed ID: 25079575
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Circulating microRNAs as biomarkers for rituximab therapy, in neuromyelitis optica (NMO).
    Vaknin-Dembinsky A; Charbit H; Brill L; Abramsky O; Gur-Wahnon D; Ben-Dov IZ; Lavon I
    J Neuroinflammation; 2016 Jul; 13(1):179. PubMed ID: 27393339
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy.
    Salzer J; Svenningsson R; Alping P; Novakova L; Björck A; Fink K; Islam-Jakobsson P; Malmeström C; Axelsson M; Vågberg M; Sundström P; Lycke J; Piehl F; Svenningsson A
    Neurology; 2016 Nov; 87(20):2074-2081. PubMed ID: 27760868
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Risk of COVID-19 infection in MS and neuromyelitis optica spectrum disorders.
    Fan M; Qiu W; Bu B; Xu Y; Yang H; Huang D; Lau AY; Guo J; Zhang MN; Zhang X; Yang CS; Chen J; Zheng P; Liu Q; Zhang C; Shi FD
    Neurol Neuroimmunol Neuroinflamm; 2020 Sep; 7(5):. PubMed ID: 32503092
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Extending rituximab dosing intervals in patients with MS during the COVID-19 pandemic and beyond?
    Maarouf A; Rico A; Boutiere C; Perriguey M; Demortiere S; Pelletier J; Audoin B;
    Neurol Neuroimmunol Neuroinflamm; 2020 Sep; 7(5):. PubMed ID: 32587103
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Posterior reversible encephalopathy syndrome after rituximab infusion in neuromyelitis optica.
    Sánchez-Carteyron A; Alarcia R; Ara JR; Martín J
    Neurology; 2010 May; 74(18):1471-3. PubMed ID: 20439850
    [No Abstract]   [Full Text] [Related]  

  • 57. Disease course, progression and activity of neuromyelitis optica (NMOSD) in patients who were treated with Rituximab, 6 and 12 months after receiving the first dose of drug, in Isfahan city.
    Ashtari F; Mehdipour R; Shaygannejad V; Mansourian M
    Mult Scler Relat Disord; 2019 Sep; 34():77-82. PubMed ID: 31233958
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Favorable outcome of granulocyte colony-stimulating factor use in neuromyelitis optica patients presenting with agranulocytosis in the setting of rituximab.
    Mealy MA; Levy M
    J Neuroimmunol; 2015 Oct; 287():29-30. PubMed ID: 26439958
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Treating patients with multiple sclerosis during the COVID-19 pandemic: Assessing the expert recommendations.
    Guevara C; Villa E; Rosas CS; Diaz V; Naves R
    Mult Scler Relat Disord; 2020 Aug; 43():102224. PubMed ID: 32464582
    [No Abstract]   [Full Text] [Related]  

  • 60. Mild or no COVID-19 symptoms in cladribine-treated multiple sclerosis: Two cases and implications for clinical practice.
    De Angelis M; Petracca M; Lanzillo R; Brescia Morra V; Moccia M
    Mult Scler Relat Disord; 2020 Oct; 45():102452. PubMed ID: 32823148
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.